Searched for
DRL Q3
Best Ring Lights to brighten up your content with Versatile Ring lightsThis is a curated article listing the best ring lights typically focuses on providing readers with a range of options to suit different nee...- Dr Reddy’s shares tumble 5% as Q4 numbers fail to impress analysts. Should you buy, sell or hold?Dr Reddy’s Share Price: The company said that the jump in YoY net profit was largely driven by growth in global generics revenues in North ...
- Dr Reddy's Q3 Results: Net profit rises 11% YoY to Rs 1,379 crore, meets estimatesDRL Q3 Results: The profit was slightly above the ET Now poll estimate of Rs 1,337 crore. Revenue from operations increased 7% year-on-year...
- Dr Reddy’s Q3 Results Preview: Profit may drop on lower Revlimid sales, higher costsThe drugmaker is expected to report a 1.1% YoY drop in consolidated net profit to Rs 1,247 crore, according to the average of estimates giv...
- Dr Reddy's Q3 Results: PAT jumps 77% YoY to Rs 1,247 crore, beats estimatesAn ET Now poll had showed that analysts were expecting PAT at Rs 910 crore and revenue at Rs 5,830 crore.
- DRL Q3 Results: Drugmaker posts 25 times rise in PAT at Rs 709 cr, in line with estimatesThe revenue from operations came in at Rs 5,103 crore, up 8.3 per cent against Rs 4,711 crore in the corresponding quarter last year.
- DRL Q3 Results Preview: Profit may grow 25% YoY; margin likely to fallEdelweiss sess profit rising 26.5 per cent YoY to Rs 780 crore. It sees sales rising 12.2 per cent YoY to Rs 5,531 crore. The brokerage see...
- How did India's Big Pharma fare in the December Quarter?Sun Pharma reported its highest-ever quarterly sales, and Cipla posted the highest-ever Ebitda margin in the company's recent history. Lupi...
- Nifty earnings: HDFC drops 2% ahead of Q3 results, DRL surges 6% despite quarterly lossHDFC stock was trading in the red ahead of its third-quarter results.
- Dr Reddy's Q3 takeaways: Impairment hurts bottom line, profit margin improvesAnalysts were largely expecting an 8-10 per cent rise in net profit for the quarter.
- Dr Reddy’s Lab shares up post Q1 results; should you invest?Global brokerage firm CLSA maintained ‘Buy’ on DRL with a target price of Rs 3,330.
- Dr Reddy’s Labs down ahead of Q1 results, here’s what to expectKotak Institutional Equities believes that the pharma company may report 49.70 per cent year-on-year rise in reported profit after tax for ...
- Reduce Dr. Reddy's Laboratories, target Rs 2,759: Elara CapitalDr. Reddy's Laboratories is a largecap company, operating in pharmaceuticals and health care sector.
- EMs, India drive Dr Reddy’s Q3 show: Key takeawaysAnalysts in an ET Now poll had projected a profit of Rs 381 crore.
- Cipla, Dr Reddy’s Q4 results today; here’s what to expectPharma firms are expected to report double-digit rise in bottomline figures.
- Planning to dump Dr Reddy's from your portfolio post Q4 numbers? Think twiceMost global brokerage firms maintained a positive view on the stock post March quarter results and CLSA has even raised its 12-month target...
- Dr Reddy's Laboratories posts 76% jump in Q2 net profit at Rs 690 croreGeneric revenues from North America was up 43 per cent at Rs 1,324 crore during the quarter, as against Rs 927 crore in the year-ago period.
- Dr Reddy's Labs: Stock presents a high-risk, high-growth bet for investorsDr Reddys Labs' fourth quarter results were better than expected. The market responded positively to this with the stock closing higher at ...
- DRL net dips 68% on price pressure, writedownDr Reddy’s Laboratories (DRL) suffered a 68% fall in Q4 net profit ended March 2008, after writing down the intangible value of the product...
- Dr Reddy’s Q3 net trebles, 9-mth revenue crosses $1bnDr Reddy’s Laboratories has gained entry into the $1-billion club with its nine months’ revenue of 2006-07.
Load More
